

Characteristic	Non-ITD N=2,569 N (%)	ITD ^{pos} N=464 N (%)	P value
Treatment Study			
CCG-2961	536 (20.9%)	74 (15.9%)	.015
AAML03P1	240 (9.3%)	30 (6.5%)	.045
AAML0531	775 (30.2%)	139 (32.1%)	.402
AAML1031	1018 (39.6%)	211 (45.5%)	.018
Age (years)			
Median (range)	9.1 (0-29.8)	13.2 (0.6-29.5)	< .001
0-1	562 (21.9%)	9 (1.9%)	< .001
2-10	898 (35.0%)	157 (33.8%)	.641
11-15	692 (26.9%)	177 (38.1%)	< .001
16-29	417 (16.2%)	121 (26.1%)	< .001
WBC x 10 ³ /μL at diagnosis, median (range)	19.2 (0.5-918.5)	66.3 (0.2-860)	< .001
Peripheral Blasts %, median (range)	32 (0-99)	63.9 (0-100)	< .001
Bone Marrow Blasts %, median (range)	65.3 (0-100)	80 (3-100)	< .001
Cytogenetic Features			
Normal karyotype	423 (18.2%)	225 (54.0%)	< .001
t(8;21)	381 (16.5%)	14 (3.4%)	< .001
Inv(16)/t(16;16)	280 (12.0%)	13 (3.1%)	< .001
11q23 rearrangements	591 (25.4%)	14 (3.4)	< .001
t(6;9)	14 (0.6%)	35 (7.5%)	< .001
Monosomy 7	48 (2.1%)	1 (0.2%)	< .001
Monosomy 5/del 5q	32 (1.4%)	1 (0.2%)	< .001
Trisomy 8	124 (5.3%)	58 (12.5%)	< .001
Other	437 (18.8%)	62 (14.9%)	.058
Unknown	329	47	
End Induction 1 Response			
CR	1961 (77.9%)	301 (66.9%)	< .001
Not in CR	557 (22.1%)	149 (33.1%)	
Unknown	51	14	
MRD End Induction 1*			
Negative	1318 (74.7%)	179 (53.6%)	< .001
Positive	447 (25.3%)	155 (46.4%)	
Unknown	804	130	
MRD End Induction 2*			
Positive	182 (12.4%)	79 (32.9%)	< .001
Negative	1285 (87.6%)	161 (67.1%)	
Unknown	1102	224	

Supplemental Table S1. Clinical, cytogenetic and initial response to therapy characteristics of non-ITD and ITD^{pos} patients. Complete remission (CR), measurable residual disease (MRD), * MRD not available for CCG-2961 patients